Human Fas Ligand/TNFSF6 Antibody

Catalog # Availability Size / Price Qty
MAB126-SP
MAB126-100
MAB126-500
Human Fas Ligand/TNFSF6 Antibody in Data
2 Images
Product Details
Citations (13)
FAQs
Supplemental Products
Reviews (2)

Human Fas Ligand/TNFSF6 Antibody Summary

Species Reactivity
Human
Specificity
Detects human Fas Ligand/TNFSF6 in ELISAs.
Source
Monoclonal Mouse IgG2B Clone # 100419
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Chinese hamster ovary cell line CHO-derived recombinant human Fas Ligand/TNFSF6
Pro134-Leu281
Accession # P48023
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Flow Cytometry
0.25 µg/106 cells
See below

Human Fas Ligand/TNFSF6 Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human Fas Ligand/TNFSF6 Biotinylated Antibody (Catalog # BAF126)

Standard: Recombinant Human Fas Ligand/TNFSF6 Protein (Catalog # 126-FL)

Neutralization
Measured by its ability to neutralize Fas Ligand/TNFSF6-induced cytotoxicity in the Jurkat human acute T cell leukemia cell line. The Neutralization Dose (ND50) is typically 1-5 ng/mL in the presence of 2 ng/mL Recombinant Human Fas Ligand/TNFSF6 and 10 µg/mL of a cross-linking antibody, Mouse poly-Histidine Monoclonal Antibody.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Examples

Flow Cytometry Detection of Fas Ligand/TNFSF6 in HEK293 Human Cell Line Transfected with Human Fas Ligand/TNFSF6 and eGFP by Flow Cytometry. View Larger

Detection of Fas Ligand/TNFSF6 in HEK293 Human Cell Line Transfected with Human Fas Ligand/TNFSF6 and eGFP by Flow Cytometry. HEK293 human embryonic kidney cell line transfected with (A) Fas Ligand/TNFSF6 or (B) irrelevant protein, and eGFP were stained with Mouse Anti-Human Fas Ligand/TNFSF6 Monoclonal Antibody (Catalog # MAB126) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). Quadrant markers were set based Mouse IgG2B Isotype Control Antibody staining (Catalog # MAB0041, data not shown). View our protocol for Staining Membrane-associated Proteins.

Neutralization Cytotoxicity Induced by Fas Ligand/TNFSF6 and Neutralization by Human Fas Ligand/TNFSF6 Antibody. View Larger

Cytotoxicity Induced by Fas Ligand/TNFSF6 and Neutralization by Human Fas Ligand/TNFSF6 Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050), Recombinant Human Fas Ligand/TNFSF6 (Catalog # 126-FL) induces cytotoxicity in the Jurkat human acute T cell leukemia cell line in a dose-dependent manner (orange line). Under these conditions, cytotoxicity elicited by Recombinant Human Fas Ligand/TNFSF6 (2 ng/mL) is neutralized (green line) by increasing concentrations of Human Fas Ligand/TNFSF6 Monoclonal Antibody (Catalog # MAB126). The ND50is typically 1-5 ng/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Fas Ligand/TNFSF6

Fas Ligand (FasL), also known as CD178, CD95L, or TNFSF6, is a 40 kDa type II transmembrane member of the TNF superfamily of proteins. Its ability to induce apoptosis in target cells plays an important role in the development, homeostasis, and function of the immune system (1). Mature human Fas Ligand consists of a 179 amino acid (aa) extracellular domain (ECD), a 22 aa transmembrane segment, and a 80 aa cytoplasmic domain (2). Within the ECD, human Fas Ligand shares 81% and 78% aa sequence identity with mouse and rat Fas Ligand, respectively. Both mouse and human Fas Ligand are active on mouse and human cells (2, 3). Fas Ligand is expressed on the cell surface as a nondisulfide-linked homotrimer on activated CD4+ Th1 cells, CD8+ cytotoxic T cells, and NK cells (1). Fas Ligand binding to Fas/CD95 on an adjacent cell triggers apoptosis in the Fas‑expressing cell (2, 4). Fas Ligand also binds DcR3 which is a soluble decoy receptor that interferes with Fas Ligand-induced apoptosis (5). Fas Ligand can be released from the cell surface by metalloproteinases as a 26 kDa soluble molecule which remains trimeric (6, 7). Shed Fas Ligand retains the ability to bind Fas, although its ability to trigger apoptosis is dramatically reduced (6, 7). In the absence of TGF‑ beta, however, Fas Ligand/Fas interactions instead promote neutrophil-mediated inflammatory responses (3, 8). Fas Ligand itself transmits reverse signals that costimulate the proliferation of freshly antigen-stimulated T cells (9). Fas Ligand-induced apoptosis plays a central role in the development of immune tolerance and the maintance of immune privileged sites (10). This function is exploited by tumor cells which evade immune surveillance by upregulating Fas Ligand to kill tumor infiltrating lymphocytes (8, 11). In gld mice, a Fas Ligand point mutation is the cause of severe lymphoproliferation and systemic autoimmunity (12, 13).

References
  1. Lettau, M. et al. (2008) Curr. Med. Chem. 15:1684.
  2. Takahashi, T. et al. (1994) Int. Immunol. 6:1567.
  3. Seino, K-I. et al. (1998) J. Immunol. 161:4484.
  4. Suda, T. et al. (1993) Cell 75:1169.
  5. Pitti, R.M. et al. (1998) Nature 396:699.
  6. Schneider, P. et al. (1998) J. Exp. Med. 187:1205.
  7. Tanaka, M. et al. (1998) Nature Med. 4:31.
  8. Chen, J-J. et al. (1998) Science 282:1714.
  9. Suzuki, I. and P.J. Fink (2000) Proc. Natl. Acad. Sci. USA 97:1707.
  10. Ferguson, T.A. and T.S. Griffith (2006) Immunol. Rev. 213:228.
  11. Ryan, A.E. et al. (2005) Cancer Res. 65:9817.
  12. Takahashi, T. et al. (1994) Cell 76:969.
  13. Lynch, D.H. et al. (1994) Immunity 1:131.
Entrez Gene IDs
356 (Human); 14103 (Mouse); 25385 (Rat)
Alternate Names
apoptosis (APO-1) antigen ligand 1; Apoptosis antigen ligand; APT1LG1CD95L; APTL; CD178 antigen; CD178; CD95L; CD95-L; Fas antigen ligand; Fas ligand (TNF superfamily, member 6); Fas Ligand; FASLCD95 ligand; FASLG; TNFSF6; TNFSF6FasL; tumor necrosis factor (ligand) superfamily, member 6; tumor necrosis factor ligand superfamily member 6

Product Datasheets

Citations for Human Fas Ligand/TNFSF6 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

13 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Leucine-rich repeat neuronal protein-1 suppresses apoptosis of gastric cancer cells through regulation of Fas/FasL
    Authors: B Liu, Y Zhang, Y Fan, S Wang, Z Li, M Deng, C Li, J Wang, R Ma, X Wang, Y Wang, L Xu, K Hou, X Che, Y Liu, X Qu
    Cancer Sci., 2019;110(7):2145-2155.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  2. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer
    Authors: M Kim, S Pyo, CH Kang, CO Lee, HK Lee, SU Choi, CH Park
    PLoS ONE, 2018;13(6):e0198347.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  3. Immunological Properties of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
    Authors: M Idelson, R Alper, A Obolensky, N Yachimovic, J Rachmilewi, A Ejzenberg, E Beider, E Banin, B Reubinoff
    Stem Cell Reports, 2018;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  4. Combination of IAP antagonist and IFN? activates novel caspase-10- and RIPK1-dependent cell death pathways
    Authors: MC Tanzer, N Khan, JA Rickard, N Etemadi, N Lalaoui, SK Spall, JM Hildebrand, D Segal, M Miasari, D Chau, WL Wong, M McKinlay, SK Chunduru, CA Benetatos, SM Condon, JE Vince, MJ Herold, J Silke
    Cell Death Differ, 2017;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  5. Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice
    Authors: ME Guicciardi, A Krishnan, SF Bronk, P Hirsova, TS Griffith, GJ Gores
    Cell Death Dis, 2017;8(1):e2535.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  6. Granulocytic myeloid derived suppressor cells from human cord blood modulate T-helper-cell response towards an anti-inflammatory phenotype
    Authors: N Köstlin, M Vogelmann, B Spring, J Schwarz, J Feucht, C Härtel, TW Orlikowsky, CF Poets, C Gille
    Immunology, 2017;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  7. Interleukin-10-producing LAG3(+) regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis
    Authors: S Nakachi, S Sumitomo, Y Tsuchida, H Tsuchiya, M Kono, R Kato, K Sakurai, N Hanata, Y Nagafuchi, S Tateishi, H Kanda, T Okamura, K Yamamoto, K Fujio
    Arthritis Res. Ther., 2017;19(1):97.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  8. The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice.
    Authors: Zheng J, Wu W, Liu Y, Xiang Z, Liu M, Chan K, Lau S, Lam K, To K, Chan J, Li L, Chen H, Lau Y, Yuen K, Tu W
    PLoS ONE, 2015;10(8):e0135999.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  9. Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells.
    Authors: Yang, Kai-Lin, Wang, Yu-Shan, Chang, Chao-Chu, Huang, Su-Chen, Huang, Yi-Chun, Chi, Mau-Shin, Chi, Kwan-Hwa
    PLoS ONE, 2013;8(4):e61797.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  10. Potent anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins.
    Authors: Inoue T, Tashiro Y, Takeuchi M
    Int. J. Oncol., 2011;38(5):1299-306.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  11. KiSS1 metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to Akt, tumor necrosis factor family ligand expression, and apoptosis.
    Authors: Navenot JM, Fujii N, Peiper SC
    Mol. Pharmacol., 2009;75(5):1074-83.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  12. Inhibition of p38 mitogen-activated protein kinase unmasks a CD30-triggered apoptotic pathway in anaplastic large cell lymphoma cells.
    Authors: Krysov SV, Krysov&lt;/LastName&gt;&lt;ForeNam SV&lt;/Initia, Rowley TF, Al-Shamkhani A
    Mol. Cancer Ther., 2007;6(2):703-11.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization
  13. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation.
    Authors: Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK
    Cell Death Differ., 2006;13(10):1789-801.
    Species: Human
    Sample Types: Whole Cells
    Applications: Neutralization

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human Fas Ligand/TNFSF6 Antibody

Average Rating: 4.5 (Based on 2 Reviews)

5 Star
50%
4 Star
50%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human Fas Ligand/TNFSF6 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human Fas Ligand/TNFSF6 Antibody
By Anonymous on 07/17/2018
Application: B/N Sample Tested: Human NKT cell,Human CAR-T cell,activated CAR-T cell Species: Human

the Fas/FasL pathways in CAR-T cell apoptosis is significant rescued upon blockade by combined Anti-Fas and Anti-FasL Antibody.


Human Fas Ligand/TNFSF6 Antibody
By Anonymous on 11/04/2016
Application: IHC Sample Tested: Adult lung Species: Human